Cerlapirdine

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Cerlapirdine
Cerlapirdine.svg
Systematic (IUPAC) name
N,N-dimethyl-3-[(3-naphthalen-1-ylsulfonyl-2H-indazol-5-yl)oxy]propan-1-amine
Clinical data
Legal status
  • Non-regulated
Identifiers
CAS Number 925448-93-7
925447-04-7 (hydrochloride)
ATC code none
PubChem CID: 16071605
ChemSpider 17231095
KEGG D10099 YesY
ChEMBL CHEMBL2103880
Chemical data
Formula C22H23N3O3S
Molecular mass 409.501 g/mol
  • O=S(=O)(c1c2cc(OCCCN(C)C)ccc2nn1)c4c3ccccc3ccc4
  • InChI=1S/C22H23N3O3S/c1-25(2)13-6-14-28-17-11-12-20-19(15-17)22(24-23-20)29(26,27)21-10-5-8-16-7-3-4-9-18(16)21/h3-5,7-12,15H,6,13-14H2,1-2H3,(H,23,24)
  • Key:NXQGEDVQXVTCDA-UHFFFAOYSA-N

Cerlapirdine (USAN; SAM-531, WAY-262,531, PF-05212365) is a drug which is under development by Wyeth/Pfizer for the treatment of cognitive disorders associated with Alzheimer's disease and schizophrenia.[1] As of 2011, it is in phase II clinical trials, and has demonstrated a trend toward efficacy along with a good side effect profile and no incidence of serious adverse events.[2] It exerts its effects by acting as a selective 5-HT6 receptor antagonist.[1]

See also

References

  1. 1.0 1.1 Lua error in package.lua at line 80: module 'strict' not found.
  2. Lua error in package.lua at line 80: module 'strict' not found.